HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

Supplementary Data

• Supplement - Supplementary Table S1. Summary of eight pazopanib (monotherapy) clinical studies included in the discovery pharmacogenetic liver toxicity analysis Supplementary Table S2. Summary of 23 pazopanib clinical studies included in the confirmatory pharmacogenetic liver toxicity analysis Supplementary Table S3. Primary tumor types for patients in the pharmacogenetic analyses Supplementary Table S4. Association between HLA-B*57:01 carriage and ALT elevation in pazopanib-treated patients with cancer. Sensitivity analyses in the combined dataset excluding 192 patients with baseline ALT>ULN Supplementary Table S5. Assessment of patients who had concurrent ALT (>3×ULN) and total bilirubin (>2×ULN) elevations Supplementary Table S6. Association between rs1800625 (chr6:32152442) genotype and ALT elevation in pazopanib-treated patients with cancer Supplementary Table S7. Joint analysis of HLA-B*57:01 and rs1800625 (chr6:32152442) genotype association with time to ALT>3xULN in pazopanib-treated patients with cancer Supplementary Figure S1. Genome-wide association study (GWAS) of common genetic variants (minor allele frequency {greater than or equal to}5%) associated with time to first ALT>3×ULN.